Xiaoqing Yu

Associate Professor

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Cancer transcriptomic data are widely leveraged to evaluate the prognostic relevance of targeted genes. However, most basic and translational studies continue to rely on univariable survival analysis, which often fails to capture the full prognostic potential of genes or account for their biological context. Recognizing the complexity of revealing multifaceted prognostic effects, especially when incorporating covariates and variable thresholds, we present the Cancer Gene Prognosis Atlas (CGPA), an interactive tool specifically designed for basic and molecular cancer researchers. CGPA provides an intuitive, user-friendly interface that enables in-depth, customizable prognostic analysis across cancer types. Beyond single-gene analyses, it supports data-driven exploration of gene pairs and gene–hallmark relationships, providing insights into key mechanisms such as synthetic lethality and immunosuppression. CGPA further extends its capabilities to assess multigene panels using both public and user-provided data and includes a dedicated portal for cancer immunotherapy datasets. Collectively, CGPA’s comprehensive yet user-friendly toolkit enables researchers to interrogate the prognostic landscape of genes with precision, tailor analyses to specific biological hypotheses, and accelerate biomarker discovery and validation through the integration of both mechanisticically-informed and data-driven approaches. Implications: CGPA is a streamlined, interactive platform for multicontext gene-centric prognostic analysis, simplifying biomarker discovery and validation for molecular and basic cancer scientists and bridging a critical gap in translational cancer research.

Year:

2026

While immunotherapy has become the standard of care for lung adenocarcinoma (LUAD) patients without actionable genomic alterations, only a subset of patients benefits from a long-lasting response to immunotherapy. Activation of p53-related signals has emerged as a potential mediator of the lung tumor microenvironment (TME). Given that mutant-p53 interacts with p73 extensively and TAp73-deficient mice develop LUAD, we engineered a mouse model with conditional deletion of TAp73 to understand the interactions of the p53 family in the TME and in metabolic pathways that impact anti-tumor immunity. We demonstrated that TAp73 exerts a tumor-suppressive role in Kras G12D -driven LUAD by regulating lipid metabolism in the TME. We identified a TAp73-driven transcriptional signature involving genes in the arachidonic acid metabolism pathway operational in tumor-associated macrophages that favors T-cell activation and thus anti-tumor immunity. Similar transcriptional changes are seen in macrophages from LUAD patients with p53 mutations and in association with response to immunotherapy. SIGNIFICANCE There is a need to understand how the LUAD TME impacts patient response to immunotherapy. We identified a transcriptional program enacted by TAp73 in tumor alveolar macrophages that supports T-cell activation. Transcriptional and metabolomic data from LUAD patients supports the relevance of this program in response to immune checkpoint inhibition.

Year:

2025

Prolonged or indefinite systemic therapy remains standard for advanced clear cell renal cell carcinoma (ccRCC), often resulting in cumulative toxicities and treatment burden. We conducted a single-arm phase 2 trial of a fixed-duration regimen of pembrolizumab plus high-dose interleukin-2 in treatment-naive advanced ccRCC. Among 26 patients treated, after a median follow-up of 76.4 months, the objective response rate was 73%, with complete responses in 42%. Median overall survival was not reached, with 5-year survival of 73%; median progression-free survival was 19.3 months; and median treatment-free survival was 23.8 months, with 42% of patients remaining treatment-free at 5 years. No grade 5 adverse events occurred, and no patient with durable disease control experienced persistent grade ≥2 toxicities. Correlative analyses identified immune patterns associated with durable benefit, including enrichment of CD16⁺ natural killer cells, suppression of PD-1⁺ T-cell frequencies, and coordinated chemokine, complement, and PKC/TGF-β pathway activation. ClinicalTrials.gov identifier: NCT02964078.

Year:

2025

Supplementary Figure 1. GBM-infiltrating Neutrophils are immunosuppressive cells. Supplementary Figure 2. CD71 identifies a cluster of hypoxic and glycolytic Neutrophils. Supplementary Figure 3. CD71+ Neutrophils are long-lived and mature cells that are found in the hypoxic-glycolytic niches of brain tumors. Supplementary Figure 4. CD71+ Neutrophils are immunosuppressive cells within the GBM TME. Supplementary Figure 5. CD71 expression and the immunosuppressive ability cannot be induced in CD71 − Neutrophils. Supplementary Figure 6. Hypoxic CD71+ Neutrophils are long-lived cells but CD71 is not required for their immunosuppressive ability. Supplementary Figure 7. Hypoxia boosts the glycolytic metabolism of CD71+ Neutrophils. Supplementary Figure 8. Extracellular lactate and histone acetylation are not involved in the regulation of the immunosuppressive ability of hypoxic CD71+ Neutrophils. Supplementary Figure 9. Isosafrole specifically inhibits the immunosuppressive ability of hypoxic CD71+ Neutrophils. Supplementary Figure 10. Human CD71+ neutrophils are glycolytic and immunosuppressive cells.

Year:

2025

Despite functional heterogeneity, the high frequency of intratumoral neutrophils predicts poor clinical outcomes. The tumor microenvironment reprograms neutrophils into immunosuppressive subsets that hinder anticancer immunity, thereby contributing to tumor growth and resistance to immunotherapies. However, the mechanisms underlying neutrophil reprogramming remain elusive. In this study, we report that the immunosuppressive ability of brain tumor–infiltrating neutrophils was restricted to a highly glycolytic and long-lived subset expressing CD71, which acquired immunosuppressive properties in response to hypoxia. Mechanistically, hypoxia boosted glucose metabolism in CD71 + neutrophils, leading to high lactate production. Lactate caused histone lactylation, which subsequently regulated arginase-1 expression, required for T-cell suppression. Targeting histone lactylation with the antiepileptic drug isosafrole blocked CD71 + neutrophil immunosuppressive ability, delayed tumor progression, and sensitized brain tumors to immunotherapy. A distinctive gene signature characterizing immunosuppressive CD71 + neutrophils correlated with adverse clinical outcomes across diverse human malignancies. This study identifies histone lactylation as a potential therapeutic target to counteract neutrophil-induced immunosuppression within tumors. Significance: Neutrophils are critical contributors to the immunosuppressive microenvironment that restricts the effects of promising immunotherapies in glioblastoma. Our study identifies hypoxia-driven histone lactylation as a potential target to block immunosuppressive neutrophils and boost the effects of immunotherapy in glioblastoma and in other cancer settings beyond brain tumors.

Year:

2025

Metadata of the brain and extracranial melanoma metastases (Visium), and Merkel Cell Carcinoma (CosMx) samples used in the spatialGE analyses. The file also contains the accession numbers and links to the data used in this work.

Year:

2025

Compressed file containing Excel workbooks with results from the Spatial gradients (STgradient), Spatial gene set enrichment (STenrich), and Differential expression (STdiff) modules. An additional workbook is included with the results testing from gradients of expression with respect to the astrocyte-dominated region in sample1_MB14_A (brain melanoma metastasis data set).

Year:

2025

Spatial transcriptomics (ST) is a powerful tool for understanding tissue biology and disease mechanisms. However, the advanced data analysis and programming skills required can hinder researchers from realizing the full potential of ST. To address this, we developed spatialGE, a web application that simplifies the analysis of ST data. The application spatialGE provided a user-friendly interface that guides users without programming expertise through various analysis pipelines, including quality control, normalization, domain detection, phenotyping, and multiple spatial analyses. It also enabled comparative analysis among samples and supported various ST technologies. The utility of spatialGE was demonstrated through its application in studying the tumor microenvironment of two data sets: 10× Visium samples from a cohort of melanoma metastasis and NanoString CosMx fields of vision from a cohort of Merkel cell carcinoma samples. These results support the ability of spatialGE to identify spatial gene expression patterns that provide valuable insights into the tumor microenvironment and highlight its utility in democratizing ST data analysis for the wider scientific community. Significance: The spatialGE web application enables user-friendly exploratory analysis of spatial transcriptomics data by using a point-and-click interface to guide users from data input to discovery of spatial patterns, facilitating hypothesis generation.

Year:

2025

Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8 + T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40 + IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40 + IFNβ in phase I clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in non–small cell lung cancer (NSCLC) patients. This approach to simultaneously target two major DC-activating pathways has the potential to significantly affect the solid tumor immunotherapy landscape.

Year:

2025

Transcription factor deregulation potently drives melanoma progression by dynamically and reversibly controlling gene expression programs. We previously identified the small MAF family transcription factor MAFG as a putative driver of melanoma progression, prompting an in-depth evaluation of its role in melanoma. MAFG expression increases with human melanoma stages and ectopic MAFG expression enhances the malignant behavior of human melanoma cells in vitro, xenograft models, and genetic mouse models of spontaneous melanoma. Moreover, MAFG induces a melanoma phenotype switch from a melanocytic state to a more dedifferentiated state. Mechanistically, MAFG interacts with the lineage transcription factor MITF which is required for the pro-tumorigenic effects of MAFG. MAFG and MITF co-occupy numerous genomic sites and MAFG overexpression influences the expression of genes harboring binding sites for the MAFG∼MITF complex. These results establish MAFG as a potent driver of melanomagenesis through dimerization with MITF and uncover an unappreciated mechanism of MITF regulation. Significance statement MITF is critically involved in melanoma progression and phenotype switching. We discovered that MAFG interacts with MITF to influence expression of MITF target genes and facilitate a shift toward a dedifferentiated melanoma cell state. This study demonstrates that MAFG promotes melanomagenesis by influencing MITF activity, an unappreciated mechanism of MITF regulation.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (30)

Rami Komrokji

Vice chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Xuefeng Wang

Associate Member/Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Elizabeth Hyjek

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Alessandra De Leo

The Wistar Institute

UNITED STATES
View details

Harshani Lawrence

Scientific and Managing Director, Chemical Biology Core

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

michela perego

Research Assistant Professor

The Wistar Institute

UNITED STATES
View details

Eric Lau

Associate Professor

Knight Cancer Institute, Oregon Health and Science University

UNITED STATES
View details

Michael Major

Alan A. and Edith L. Wolff Professor

Washington University in St. Louis

UNITED STATES
View details

Qianxing Mo

Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Filippo Veglia

Assistant Professor

The Wistar Institute

UNITED STATES
View details

Anders Berglund

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Elsa Flores

Associate Center Director, Basic Science

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Dae Hyun Lee

Assistant Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Erika Eksioglu

Independent investigator/researcher

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Alexander Anderson

Department Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Daniel Murphy

Professor of Lung Cancer & Mesothelioma

University of Glasgow

UNITED KINGDOM
View details

aurelia rughetti

Associate Professor

Sapienza University of Rome

ITALY
View details

Roger Li

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Jose Conejo-Garcia

Duke Science and Technology Scholar

Duke Medicine

UNITED STATES
View details

Steven Eschrich

Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Marco Napoli

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Michael Schell

Senio Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Inna Smalley

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paulo Rodriguez

Senior Member-Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

James K. C. Liu

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Kenneth Tsai

Vice Chair of Research, Senior Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Paul Stewart

Research Associate Professor

University of Utah

UNITED STATES
View details

Christopher Cubitt

Core Staff Scientist

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Daesung Lee

-

UNITED STATES
View details